Freeline Therapeutics is a UK-based biotechnology company that develops liver-directed gene therapies for bleeding disorders and other diseases. Its therapies are based on a next-generation proprietary AAV vector platform, specifically a gene therapy to treat haemophilia B.
The company plans to raise $125 million by offering 7.4 million ADSs at a price range of $16 to $18. At the midpoint of the proposed range, Freeline Therapeutics would have a fully diluted market value of $574 million. Freeline has previously already raised $278 million in private funding.
The company’s lead candidate, FLT180a, an investigational gene therapy medicinal product candidate for the treatment of hemophilia B, is currently in a Phase 1/2 trial and has dosed 10 patients as of June 15, 2020.
The pipeline:
Gene therapy for haemophilia B: Haemophilia B (FLT180a)
FLT180a is a next-generation AAV gene therapy for patients with moderate to severe haemophilia B. An ongoing Phase 1/2 trial is currently enrolling patients in the UK with the objective of evaluating safety and efficacy of FLT180a.
Gene therapy for Fabry Disease: Fabry Disease (FLT190)
Preclinical data using our gene therapy platform for expression of the enzyme a galactosidase A (GLA) has demonstrated safety and efficacy in various animal models. We plan to initiate a Phase 1/2 trial very soon to evaluate FTL190 in patients with Fabry Disease.
Gene therapy for Gaucher Disease: Gaucher Disease (FLT200)
Preclinical data using our gene therapy platform for expression of the enzyme a galactosidase A (GLA) has demonstrated safety and efficacy in various animal models. We plan to initiate a Phase 1/2 trial [very soon,] to evaluate FTL190 in patients with Fabry Disease. Study sites have been selected in the UK, US, Germany, Norway, Italy and Denmark. Safety and efficacy have not been established, nor have any of our product candidates been approved by the US Food and Drug Administration or any other regulatory agency.
Image source: Freeline Therapeutics
The ideas presented on this site do not constitute a recommendation to buy or sell any security. Investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action. You should be aware of the risks involved in stock investing, and you use the material contained herein at your own risk. Neither SYNTHETIC.COM nor any of its contributors are responsible for any errors or omissions which may have occurred. The analysis, ratings, and/or recommendations made on this site do not provide, imply, or otherwise constitute a guarantee of performance. SYNTHETIC.COM posts may contain financial reports and economic analysis that embody a unique view of trends and opportunities. Accuracy and completeness cannot be guaranteed. Investors should be aware of the risks involved in stock investments and the possibility of financial loss. It should not be assumed that future results will be profitable or will equal past performance, real, indicated or implied. The material on this website is provided for information purpose only. SYNTHETIC.COM does not accept liability for your use of the website. The website is provided on an “as is” and “as available” basis, without any representations, warranties or conditions of any kind.
